Amphera
Maastricht, Netherlands· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
EMPOWERING DENDRITIC CELLS Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer. MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour
Biologics